Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.86 | 325.43 | 72.64 | 1.02 | 1.18 | 1.53 | 3.14 | — | 5.43 | 5.61 | 2.53 | 101.71 | 77.89 | 168.60 | 143.43 | 172.99 | 131.23 | 273.08 | 625.65 | 1797.45 | 3129.43 |
| — | +21123.1% | +2215.2% | — | -78.3% | -72.7% | +24.2% | — | -93.0% | -96.7% | -98.2% | -41.2% | -40.6% | -38.3% | -77.1% | -90.4% | -95.8% | — | — | — | — | |
| P/B Ratio | 0.24 | 0.51 | 0.38 | 0.39 | 0.32 | 0.28 | 0.33 | 0.36 | 0.34 | 0.33 | 0.51 | 7.54 | 6.14 | 6.80 | 6.64 | 5.69 | 5.88 | 7.32 | 8.91 | 14.60 | 34.24 |
| — | +80.8% | +16.3% | +7.8% | -7.6% | -14.5% | -36.0% | -95.2% | -94.4% | -95.1% | -92.3% | +32.4% | +4.4% | -7.1% | -25.4% | -61.0% | -82.8% | -80.9% | -88.0% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.6% | 100.0% | -680.8% | 100.0% | 100.0% | 100.0% | 100.0% | — | -1108.2% | -1110.4% | 91.3% | -681.3% | -491.4% | -991.7% | -700.9% | -1093.8% | -798.3% | -1258.2% | -2161.4% | -4326.0% | -2471.4% |
| — | 0.0% | -780.8% | — | +109.0% | +109.0% | +9.5% | — | -125.5% | -12.0% | +113.0% | +37.7% | +38.4% | +21.2% | +67.6% | +74.7% | +67.7% | — | — | — | — | |
| Operating Margin | -450.1% | -167480.0% | -29234.6% | -224.2% | -355.1% | -510.5% | -991.4% | — | -1441.1% | -1772.3% | -324.1% | -946.2% | -719.3% | -1383.9% | -1008.5% | -1491.1% | -1058.0% | -1655.3% | -2936.8% | -5329.7% | -3128.5% |
| — | -32705.0% | -2848.8% | — | +75.4% | +71.2% | -205.9% | — | -100.4% | -28.1% | +67.9% | +36.5% | +32.0% | +16.4% | +65.7% | +72.0% | +66.2% | — | — | — | — | |
| Net Margin | -433.7% | -154400.0% | -27861.5% | -265.2% | -329.4% | -474.6% | -903.4% | — | -1330.1% | -1662.4% | -205.0% | -857.0% | -643.1% | -1260.1% | -929.9% | -1417.2% | -1030.3% | -1627.0% | -2912.4% | -5345.9% | -3111.0% |
| — | -32435.6% | -2983.9% | — | +75.2% | +71.5% | -340.7% | — | -106.8% | -31.9% | +78.0% | +39.5% | +37.6% | +22.6% | +68.1% | +73.5% | +66.9% | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.7% | -47.6% | -31.3% | -22.6% | -20.1% | -20.0% | -21.2% | -24.7% | -19.2% | -22.3% | -10.0% | -14.9% | -12.0% | -12.0% | -10.3% | -11.1% | -11.0% | -10.4% | -9.9% | -10.3% | -8.2% |
| — | -137.9% | -47.3% | +8.2% | -4.8% | +10.4% | -113.0% | -66.0% | -59.9% | -85.2% | +3.4% | -33.7% | -9.5% | -16.0% | -4.2% | -7.4% | -33.9% | -31.9% | +59.9% | — | — | |
| ROA | -42.7% | -17.5% | -13.8% | -10.9% | -10.2% | -10.6% | -11.9% | -15.3% | -13.0% | -15.9% | -7.1% | -10.7% | -8.9% | -9.1% | -7.8% | -8.4% | -8.6% | -8.3% | -8.0% | -8.5% | -6.9% |
| — | -64.7% | -16.2% | +28.6% | +21.8% | +33.1% | -66.6% | -42.8% | -46.3% | -74.4% | +8.7% | -26.4% | -3.2% | -9.0% | +2.4% | +0.2% | -25.2% | -18.9% | +39.1% | +85.2% | +55.4% | |
| ROIC | -46.0% | -24.2% | -16.7% | -11.1% | -12.6% | -11.9% | -13.1% | -15.1% | -13.7% | -15.5% | -10.6% | -11.3% | -9.4% | -9.4% | -7.9% | -8.2% | -8.2% | -8.3% | -7.9% | -7.8% | -6.5% |
| — | -104.1% | -27.1% | +26.3% | +8.0% | +23.8% | -23.8% | -33.2% | -46.2% | -64.7% | -34.4% | -38.3% | -14.8% | -13.6% | -0.3% | -5.4% | -25.1% | -12.3% | +66.1% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.87 | 1.71 | 1.13 | 0.87 | 0.73 | 0.62 | 0.53 | 0.44 | 0.25 | 0.22 | 0.19 | 0.18 | 0.16 | 0.15 | 0.14 | 0.13 | 0.12 | 0.11 | 0.10 | 0.10 | 0.09 |
| — | +174.8% | +113.2% | +96.5% | +191.2% | +183.0% | +181.0% | +145.8% | +55.2% | +45.6% | +34.3% | +36.0% | +31.9% | +37.2% | +36.7% | +35.4% | +36.0% | +27.8% | +190.5% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.59 | 2.61 | 3.51 | 3.59 | 3.57 | 3.11 | 3.13 | 3.20 | 3.16 | 4.28 | 5.68 | 5.17 | 6.69 | 7.42 | 8.10 | 7.47 | 7.23 | 9.73 | 10.16 | 8.87 | 9.39 |
| — | -16.1% | +11.9% | +11.9% | +13.1% | -27.3% | -44.9% | -38.0% | -52.8% | -42.3% | -29.8% | -30.8% | -7.5% | -23.8% | -20.3% | -15.7% | -23.0% | -24.5% | -55.0% | +293.9% | +134.4% | |
| Quick Ratio | 3.59 | 2.61 | 3.51 | 3.59 | 3.57 | 3.11 | 3.13 | 3.20 | 3.16 | 4.28 | 5.68 | 5.17 | 6.69 | 7.42 | 8.10 | 7.47 | 7.23 | 9.73 | 10.16 | 8.87 | 9.39 |
| — | -16.1% | +11.9% | +11.9% | +13.1% | -27.3% | -44.9% | -38.0% | -52.8% | -42.3% | -29.8% | -30.8% | -7.5% | -23.8% | -20.3% | -15.7% | -23.0% | -24.5% | -55.0% | +293.9% | +134.4% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -330.18 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BOLT stock.
Bolt Biotherapeutics, Inc.'s current P/E is -0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bolt Biotherapeutics, Inc.'s current operating margin is -450.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bolt Biotherapeutics, Inc.'s business trajectory between earnings reports.